(R)-4-CarboxyphenylglycineCAS# 134052-68-9 |
- Anguizole
Catalog No.:BCC1365
CAS No.:442666-98-0
- Asunaprevir (BMS-650032)
Catalog No.:BCC1374
CAS No.:630420-16-5
- Balapiravir
Catalog No.:BCC1396
CAS No.:690270-29-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 134052-68-9 | SDF | Download SDF |
PubChem ID | 6604711 | Appearance | Powder |
Formula | C9H9NO4 | M.Wt | 195.17 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | (<em>R</em>)-4CPG | ||
Solubility | Soluble to 100 mM in 1eq. NaOH and to 5 mM in water | ||
Chemical Name | 4-[(R)-amino(carboxy)methyl]benzoic acid | ||
SMILES | C1=CC(=CC=C1C(C(=O)O)N)C(=O)O | ||
Standard InChIKey | VTMJKPGFERYGJF-SSDOTTSWSA-N | ||
Standard InChI | InChI=1S/C9H9NO4/c10-7(9(13)14)5-1-3-6(4-2-5)8(11)12/h1-4,7H,10H2,(H,11,12)(H,13,14)/t7-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Moderately potent NMDA receptor antagonist. (RS)-4-Carboxyphenylglycine and (S)-4-Carboxyphenylglycine also available. |
(R)-4-Carboxyphenylglycine Dilution Calculator
(R)-4-Carboxyphenylglycine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.1237 mL | 25.6187 mL | 51.2374 mL | 102.4748 mL | 128.0935 mL |
5 mM | 1.0247 mL | 5.1237 mL | 10.2475 mL | 20.495 mL | 25.6187 mL |
10 mM | 0.5124 mL | 2.5619 mL | 5.1237 mL | 10.2475 mL | 12.8093 mL |
50 mM | 0.1025 mL | 0.5124 mL | 1.0247 mL | 2.0495 mL | 2.5619 mL |
100 mM | 0.0512 mL | 0.2562 mL | 0.5124 mL | 1.0247 mL | 1.2809 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- (RS)-4-Carboxy-3-hydroxyphenylglycine
Catalog No.:BCC6598
CAS No.:134052-66-7
- Selaginellin F
Catalog No.:BCN6420
CAS No.:1340493-24-4
- H-Ala-OtBu.HCl
Catalog No.:BCC3194
CAS No.:13404-22-3
- Methyl beta-D-fructofuranoside
Catalog No.:BCN6183
CAS No.:13403-14-0
- Phaseollin
Catalog No.:BCN4816
CAS No.:13401-40-6
- d-Laserpitin
Catalog No.:BCN3616
CAS No.:134002-17-8
- 4-Hydroxy-3,5-dimethoxybenzaldehyde
Catalog No.:BCN6186
CAS No.:134-96-3
- Lobeline Sulphate
Catalog No.:BCC8203
CAS No.:134-64-5
- (-)-Lobeline hydrochloride
Catalog No.:BCC6927
CAS No.:134-63-4
- Azaguanine-8
Catalog No.:BCC4629
CAS No.:134-58-7
- Pelargonidin chloride
Catalog No.:BCN3111
CAS No.:134-04-3
- Sodium ascorbate
Catalog No.:BCC4719
CAS No.:134-03-2
- (S)-4-Carboxyphenylglycine
Catalog No.:BCC6603
CAS No.:134052-73-6
- Ponasterone A
Catalog No.:BCN6184
CAS No.:13408-56-5
- TP-0903
Catalog No.:BCC6462
CAS No.:1341200-45-0
- INCB8761(PF-4136309)
Catalog No.:BCC1649
CAS No.:1341224-83-6
- Fmoc-Tyr(PO3Bzl2)-OH
Catalog No.:BCC3566
CAS No.:134150-51-9
- Methylcobalamin
Catalog No.:BCC5188
CAS No.:13422-55-4
- RKI-1447
Catalog No.:BCC1903
CAS No.:1342278-01-6
- Daphnelantoxin B
Catalog No.:BCN3228
CAS No.:134273-12-4
- 3,5-Dibromo-4-[3-(dimethylamino)propoxy]cinnamic acid
Catalog No.:BCN1582
CAS No.:134276-56-5
- BIMU 8
Catalog No.:BCC7928
CAS No.:134296-40-5
- Tolcapone
Catalog No.:BCC2334
CAS No.:134308-13-7
- alpha,beta-Methyleneadenosine 5'-triphosphate trisodium salt
Catalog No.:BCC7603
CAS No.:1343364-54-4
(R,S)-alpha-methyl-4-carboxyphenylglycine (MCPG) fails to block long-term potentiation under urethane anaesthesia in vivo.[Pubmed:9423922]
Neuropharmacology. 1997 Oct;36(10):1339-54.
The effects of the metabotropic glutamate receptor antagonist (R,S)-alpha-methyl-4-carboxyphenylglycine (MCPG) on the induction of long-term potentiation (LTP) in the dentate gyrus were examined under urethane anaesthesia in vivo. In experiment 1, bilateral intraventricular infusion of either 20 mM or 200 mM (R,S)-MCPG (5 microl each side) failed to block LTP in the perforant path-granule cell projection, relative to vehicle-infused controls; 30 mM D-AP5 (5 microl each side) infused in the same way as MCPG completely blocked LTP. Experiment 2, in which the contralateral perforant path-dentate gyrus pathway was used as a non-tetanized control, revealed that slight baseline changes induced by MCPG infusion were transient; again no block of LTP was obtained. The efficacy of mGluR blockade was confirmed in experiment 3, in which MCPG antagonized an increase in spontaneous activity induced by (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (ACPD). In experiment 4, significant depotentiation was induced by low frequency stimulation (5 Hz for 1 min) given 2 min after high frequency tetanization, but MCPG remained ineffective in blocking LTP after a second tetanus. In experiment 5, increasing the period of low frequency stimulation from 1 to 10 min produced greater depotentiation, but still did not unmask an MCPG-sensitive component of LTP. These experiments fail to support a role for mGluRs in the induction of LTP in the dentate gyrus under urethane anaesthesia in vivo, nor do they support the idea that a metabotropic switch controlling sensitivity to MCPG is reset by depotentiation.
(R,S)-alpha-methyl-4-carboxyphenylglycine (MCPG) blocks spatial learning in rats and long-term potentiation in the dentate gyrus in vivo.[Pubmed:8177513]
Neurosci Lett. 1994 Feb 14;167(1-2):141-4.
Recently, it was demonstrated by the use of the competitive and selective antagonist (R,S)-alpha-methyl-4-carboxyphenylglycine (MCPG) that metabotropic glutamate receptor (mGluR) activation is required to induce long-term potentiation (LTP) in the hippocampus. Accordingly, we investigated whether MCPG also inhibits spatial learning. Rats were trained on a spatial alternation task in a Y-maze with footshock reinforcement, and MCPG (0.0208 mg) was injected intracerebroventricularly prior to training and/or retention test. Animals injected pre-training are clearly impaired in retention, whereas preretention application was without effect. A state dependency could be excluded. Additionally, MCPG at the same concentration completely blocks a potentiation at perforant path/dentate gyrus synapses in vivo. These results strongly implicate a role of mGluRs in spatial learning and LTP.